Author | Santos, A. P. G. dos | |
Author | Pacheco, A. G. | |
Author | Staviack, A. | |
Author | Golub, J. E. | |
Author | Chaisson, R. E. | |
Author | Rolla, V. C. | |
Author | Kritski, A. L. | |
Author | Passos, S. R. L. | |
Author | Mello, F. C. de Queiroz | |
Access date | 2019-09-19T15:07:14Z | |
Available date | 2019-09-19T15:07:14Z | |
Document date | 2013 | |
Citation | SANTOS, A. P. G. dos et al. Safety and effectiveness of HAART in tuberculosis-HIV coinfected patients in Brazil. International Journal of Tuberculosis and Lung Disease, v. 17, n. 2, p. 192-197, Feb. 2013. | pt_BR |
ISSN | 1027-3719 | pt_BR |
URI | https://www.arca.fiocruz.br/handle/icict/35691 | |
Language | eng | pt_BR |
Publisher | International Union Against Tuberculosis and Lung Disease | pt_BR |
Rights | open access | pt_BR |
Title | Safety and effectiveness of HAART in tuberculosis-HIV co-infected patients in Brazil | pt_BR |
Type | Article | pt_BR |
DOI | 10.5588/ijtld.11.0831 | |
Abstract | BACKGROUND — Antiretroviral therapy (ART) significantly reduces tuberculosis (TB) incidence among persons with human immunodeficiency virus (HIV), but the safety and effectiveness of concomitant treatment for both diseases remain unclear. OBJECTIVE — To evaluate the impact of ART and anti-tuberculosis treatment on survival and risk of adverse events (AE) among co-infected individuals. METHODS — In a retrospective cohort study, clinical data were collected from 618 TB-HIV patients treated with rifampin, isoniazid and pyrazinamide ± ethambutol between 1 January 1995 and 31 December 2003. Patients were categorized into two groups: highly active ART (HAART) or no ART. Different HAART regimens were evaluated. Bivariate analysis, multivariate logistic regression and survival analysis using Cox proportional hazards regression were used. RESULTS — One-year mortality was lower for patients receiving HAART (adjusted hazard ratio [aHR] 0.17, 95%CI 0.09–0.31) compared to no ART. HAART increased the risk of AE (aHR 2.08, 95%CI 1.29–3.36). The odds of AE when receiving a ritonavir + saquinavir HAART regimen was eight-fold higher compared to no ART (OR 8.31, 95%CI 3.04–22.69), while efavirenz-based HAART was not associated with a significantly increased risk of AE (OR 1.42, 95%CI 0.76–2.65). CONCLUSION — HIV patients with TB have significantly better survival if they receive HAART during anti-tuberculosis treatment. Efavirenz-based HAART is associated with fewer AEs than protease inhibitor-based HAART. | pt_BR |
Affilliation | Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Institute of Thoracic Diseases. Rio de Janeiro, RJ, Brazil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Institute of Thoracic Diseases. Rio de Janeiro, RJ, Brazil. | pt_BR |
Affilliation | Johns Hopkins University. Baltimore, MD, USA. | pt_BR |
Affilliation | Johns Hopkins University. Baltimore, MD, USA. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Institute of Thoracic Diseases. Rio de Janeiro, RJ, Brazil. | pt_BR |
Affilliation | Fundação Oswaldo Cruz. Instituto de Pesquisa Clínica Evandro Chagas. Rio de Janeiro, RJ, Brasil. | pt_BR |
Affilliation | Federal University of Rio de Janeiro. Clementino Fraga Filho University Hospital. Institute of Thoracic Diseases. Rio de Janeiro, RJ, Brazil. | pt_BR |
Subject | Tuberculosis | pt_BR |
Subject | AIDS | pt_BR |
Subject | HAART | pt_BR |
Subject | Adverse events | pt_BR |
Subject | Survival | pt_BR |
e-ISSN | 1815-7920 | |
Embargo date | 2020-03-19 | |